WAY-262611 is primarily used in scientific research to study the glucagon-like peptide-1 (GLP-1) receptor. It acts as a potent and selective agonist for this receptor, making it a valuable tool for investigating pathways related to glucose metabolism and insulin secretion. Researchers utilize WAY-262611 to explore potential treatments for type 2 diabetes and obesity due to its ability to mimic the effects of GLP-1 in preclinical models. Its high selectivity helps minimize off-target effects, allowing for more accurate assessment of GLP-1 receptor function. The compound is not used clinically but supports the development and validation of new therapeutic agents targeting metabolic disorders.